MedTrace Logo

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

NCT06226545 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-03-09

Study results available
· View outcomes & findings →

Summary

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).

The primary and secondary objectives of this study are to evaluate the treatment effect, safety, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

Conditions

  • Thyroid Eye Disease
  • Graves Ophthalmopathy
  • Graves Orbitopathy
  • Thyroid Associated Ophthalmopathy
  • Endocrine System Diseases
  • Orbital Diseases
  • Proptosis
  • Eye Diseases

Interventions

DRUG

LASN01

Low dose of LASN01 will be administered intravenously.

DRUG

LASN01

High dose of LASN01 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

DRUG

LASN01

High dose of LASN01 will be administered intravenously.

Sponsors & Collaborators

  • Lassen Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2025-04-22
Completion
2025-04-22
FDA Drug
Yes

Countries

  • United States
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06226545 on ClinicalTrials.gov